- Can Apple Top Microsoft as Most Valuable Tech Firm?
- Buffett to Sell Stakes in Norfolk Southern, Union Pacific
- Do You Know Your Coca-Cola Myths?
- Electronic Arts Beats Street, Announces 1,500 Job Cuts
- Time Is Here to Look at Overseas Stocks: Bill Gross
- Home Prices Start to Stabilize In the US as Sales Pick Up
- Flaw in US Data Overstates Growth, Productivity
- Priceline Crushes Profit Forecasts; Shares Jump
- 'Modern Warfare 2' May Be Biggest Event This Year
- Warren Buffett to Sell Stakes In Union Pacific & Norfolk Southern
- Nov. 9: Unusual Volume Leaders
- The Battered Businesses Behind Housing
- Modern Warfare 2's Record-Breaking Launch
- Merck’s Mega-Monday Morning
- Why are Traders Bullish on This Food Company?
- Profiting From Natural Gas: Strategists
- S&P Stocks Trading at New 52-Week Highs
- Shopping for Answers
- Mich. ballot drive would drop insurance rates 20%
- Mutual of Omaha settles suit against Winfrey
- Northrop Grumman gets $15.6M Navy deal
- Clear Channel Outdoor posts 3Q loss
- Standard & Poor's makes changes to small-cap index
- Acadia 3Q loss narrows on revenue boost
- Status of Pfizer and Wyeth research facilities
- Salix 3Q loss widens on higher costs
- IMF grants DomRep $1.7B loan to revive economy
Text Size 
RALEIGH, N.C. - Salix Pharmaceuticals Ltd. said Monday its loss widened in the third quarter on increased research and development and sales costs.
The company lost $7.3 million, or 15 cents per share, compared with a loss of $5.4 million, or 11 cents per share, during the same period a year prior. Revenue rose 53 percent to $65.7 million from $42.9 million.
Analysts polled by Thomson Reuters expected a loss of 29 cents per share on revenue of $60.4 million.
Revenue from Xifaxan, which is approved to treat traveler's diarrhea, doubled to $42.7 million. Sales of the bowel cleansing products Osmoprep and Moviprep rose to $16.4 million from $14.8 million.
The company said its costs and expenses rose 49 percent to $71.5 million on increases in sales costs and in research spending.
Salix expects a loss of about 90 cents per share and product revenue of $230 million for the full year. Analysts polled by Thomson Reuters expect a loss of 92 cents per share on revenue of $230.2 million.
Shares of Salix gained 16 cents to $21.30 in after-hours trading after rising 20 cents to close at $21.14 during the regular trading session.
Print
Email
- Do free market libertarians really believe what they say about ethics and shareholder value? The Big Money takes a look.
- Cramer did the research and found eight stocks that lead the pack. Read on to get his top picks.
- On the anniversary of the fall of the Berlin Wall, many in the former Eastern Bloc recall communism fondly.
- Software, biotech firms, even banks are watching a particular Supreme Court argument today.
- From politicians to CEOs to companies, here's your chance to vote for the winners and losers of 2009.
- A new sinister Internet viruses can turn you into an unsuspecting collector of child pornography.
Data is a real-time snapshot *Data is delayed at least 15 minutes